JP2019530711A5 - - Google Patents

Info

Publication number

JP2019530711A5

JP2019530711A5 JP2019519652A JP2019519652A JP2019530711A5 JP 2019530711 A5 JP2019530711 A5 JP 2019530711A5 JP 2019519652 A JP2019519652 A JP 2019519652A JP 2019519652 A JP2019519652 A JP 2019519652A JP 2019530711 A5 JP2019530711 A5 JP 2019530711A5

Authority

JP

Japan

Prior art keywords

composition according

composition

amyloid

cell

pharmaceutically acceptable

Prior art date

2017-10-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 33
• 239000000203 mixture Substances 0.000 claims description 17
• 210000004027 cell Anatomy 0.000 claims description 13
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 11
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 11
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 11
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 11
• -1 2- (3-methylbenzylidene) hydrazinyl Chemical group 0.000 claims description 8
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
• 208000024827 Alzheimer disease Diseases 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 7
• 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 6
• 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 6
• 239000002552 dosage form Substances 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 239000006186 oral dosage form Substances 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
• 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
• 208000031124 Dementia Alzheimer type Diseases 0.000 claims description 2
• 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
• 238000000338 in vitro Methods 0.000 claims description 2
• 238000001727 in vivo Methods 0.000 claims description 2
• 210000002569 neuron Anatomy 0.000 claims description 2
• 208000024891 symptom Diseases 0.000 claims description 2
• 238000011282 treatment Methods 0.000 claims description 2
• 150000003839 salts Chemical class 0.000 claims 6
• 210000001519 tissue Anatomy 0.000 claims 2
• 210000000944 nerve tissue Anatomy 0.000 claims 1
• 229940079593 drug Drugs 0.000 description 2
• 238000011272 standard treatment Methods 0.000 description 1